Tesamorelin

01 · What it is

Tesamorelin is a synthetic analogue of human growth hormone-releasing hormone — the full 44-residue sequence, modified at the N-terminus with a trans-3-hexenoyl group that protects it from cleavage by dipeptidyl peptidase-4 ^4,5. It acts on the growth hormone-releasing hormone receptor of anterior pituitary somatotrophs, stimulating synthesis and pulsatile release of endogenous growth hormone, which drives hepatic IGF-1 production ¹.

It is the only compound in this roadmap with an uncontested regulatory approval. In November 2010 the US Food and Drug Administration approved tesamorelin as Egrifta for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy ⁶. As of 2024 it remained the only FDA-approved therapy for abdominal fat accumulation in people with HIV ¹⁸.

That approval is narrow, and the distance between it and the way GHRH analogues are discussed generally is the substance of this guide. Tesamorelin was approved for one population, defined by disease and by measured visceral adipose tissue, on the strength of a phase 3 programme with an imaging endpoint. It was not approved for body composition in healthy adults, for athletic recovery, or for ageing, and where it has been tested outside its indication the results have been mixed: a 2025 randomised study in people with HIV and abdominal obesity found that waist circumference fell but cognitive benefits did not differ significantly between groups ¹⁹.

What makes tesamorelin genuinely useful to anyone reading about this class is that it shows what a complete evidence base looks like. A defined population. A pre-specified endpoint. Health technology assessment by an independent agency ^9,10. A catalogued hepatic safety profile ¹¹. Post-marketing studies that extended the science and, on occasion, failed to confirm a hoped-for benefit ¹⁹. Nothing else in Families A or B has any of that.

02 · Evidence at a glance

Evidence grade

Approved Pharma

Structure

GHRH(1-44) analogue with trans-3-hexenoyl N-terminal modification ^4,5

Molecular target

Growth hormone-releasing hormone receptor, anterior pituitary ¹

FDA approval

November 2010, as Egrifta ⁶

Approved indication

Reduction of excess abdominal fat in HIV-infected patients with lipodystrophy ⁶

Approved population definition

Waist circumference and CT-confirmed visceral adipose tissue thresholds ¹⁰

Independent HTA review

Yes — Canadian Agency for Drugs and Technologies in Health ^9,10

Post-marketing research

NAFLD, fat quality, integrase inhibitor co-therapy, neurocognition ^{13,14,15,18,19}

Result outside indication

Null for neurocognitive benefit ¹⁹

Hepatic safety

Catalogued in LiverTox ¹¹

WADA status

GHRH analogues fall under prohibited peptide hormones and releasing factors

03 · Mechanism of action

GHRH receptor agonism, with pulsatility preserved

Tesamorelin binds the growth hormone-releasing hormone receptor on pituitary somatotrophs and stimulates the synthesis and release of endogenous growth hormone ^1,7. The distinction from administering growth hormone directly is not cosmetic. Growth hormone is secreted physiologically in pulses, and pulsatile and continuous exposure have different downstream consequences at the liver and in adipose tissue. A GHRH analogue works upstream of that pattern, leaving pituitary feedback loops and somatostatin restraint intact, which is the mechanistic rationale for the whole class.

Why the molecule needed modification

Native GHRH and its 1-29 fragment are cleaved rapidly by dipeptidyl peptidase-4, giving circulating half-lives measured in minutes ². Tesamorelin’s trans-3-hexenoyl modification at the N-terminus blocks that cleavage without changing the receptor-binding region ⁵. This is a conventional and well-understood approach to peptide stabilisation, and it is worth naming precisely because the other compounds in this family solve the same problem in different ways with very different evidence behind them.

Lipolysis and visceral adipose tissue

The approved effect is a reduction in visceral adipose tissue, mediated through growth hormone-driven lipolysis. Growth hormone stimulates hormone-sensitive lipase activity and shifts substrate use toward fat oxidation, with visceral fat depots more responsive than subcutaneous depots — which is why the label and the trial entry criteria are framed in terms of visceral adipose tissue measured by computed tomography rather than weight ¹⁰. Later work shows the effect is not purely quantitative: over 26 weeks, visceral and subcutaneous adipose tissue density increased in tesamorelin-treated participants only, indicating a change in fat quality alongside the change in quantity ¹⁵.

Hepatic effects, and a mechanism identified after approval

The most substantial post-approval mechanistic work concerns the liver. In HIV-associated non-alcoholic fatty liver disease, tesamorelin produced changes in hepatic gene expression that correlated with improved fibrosis-related gene scores ¹³, and a targeted proteomic and transcriptomic analysis showed downregulation of hepatic gene sets involved in inflammation, tissue repair and cell division, with reductions in plasma VEGFA and CSF1 correlating with response ¹⁴. That is a mechanism characterised in human tissue, in a population receiving the drug — a standard almost nothing else in this roadmap meets.

Glucose, and the constraint that comes with the mechanism

Growth hormone antagonises insulin action. Any compound that raises growth hormone raises the question of glucose tolerance, and this is the class’s intrinsic liability rather than an idiosyncratic side effect. Tesamorelin has major effects on glucose and lipid metabolism ¹¹, and hyperglycaemia is among the adverse events tracked in post-marketing studies ¹⁸. A mechanism that mobilises fat by raising growth hormone cannot be separated from its effect on insulin sensitivity.

04 · Key research findings

The approval-supporting programme. The phase 3 evidence in HIV-associated lipodystrophy was reviewed contemporaneously in the pharmacology and drug-evaluation literature ^7,8,12 and subsequently by an independent health technology assessment agency, which assessed both clinical benefit and cost-effectiveness against a defined population: excess visceral adipose tissue, identified by waist circumference of 95 cm or more in males and 94 cm or more in females and confirmed at more than 130 cm² by computed tomography, in treatment-experienced patients ^9,10.

The specificity of that population definition is the point — this is what an indication looks like when it is earned rather than asserted.

Fat quality, not only quantity. In a 26-week analysis, baseline visceral and subcutaneous adipose tissue density were similar across arms, and density increased in tesamorelin-treated participants only ¹⁵.

A finding that would have been invisible to a weight or waist endpoint, and an example of what post-marketing research adds after an approval is in place.

Liver disease — the most important post-approval development. Tesamorelin was described in 2020 as the first strategy shown to be effective against non-alcoholic fatty liver disease in the population with HIV, with hepatic expression changes correlating with improved fibrosis-related gene score ¹³. Follow-up proteomic and transcriptomic work delineated the response pathways ¹⁴, and the finding drew commentary in the HIV literature ¹².

This is a genuine extension of the science after approval, and it was pursued through mechanism in human tissue rather than through extrapolation.

Co-administration with modern antiretrovirals. A 2024 study examined efficacy and safety in people with HIV taking integrase inhibitors — the current standard of care, and a class associated with weight gain — and reported that tesamorelin was well tolerated with a similar frequency of adverse events, including hyperglycaemia, between groups ¹⁸.

Keeping an approved drug’s evidence current as the treatment landscape changes is ordinary in pharmaceutical development and essentially unheard of among the compounds in Family A.

A null result outside the indication. A 2025 clinical trial examined tesamorelin for neurocognitive impairment in people with HIV and abdominal obesity. Waist circumference fell, and cognitive benefits did not differ significantly between groups. The authors noted the limitations of insufficient power and the absence of a placebo arm, and concluded that the study suggested no clear benefit of short-term abdominal obesity reduction with tesamorelin on neurocognition ¹⁹.

The most instructive result in this guide: an approved compound, tested outside what it was approved for, did not deliver — and the negative result was published.

Post hoc analysis by fat distribution. A phase 3 post hoc analysis examined participants receiving tesamorelin for 26 weeks split by the presence of dorsocervical fat, examining whether efficacy differed by fat distribution pattern ¹⁷.

Ordinary secondary analysis, included here because it illustrates the depth of the dataset an approval programme leaves behind.

Detection and the doping literature. Tesamorelin appears alongside sermorelin and CJC-1295 in in vitro metabolism and urine detection method development for anti-doping ^16,24.

The same analytical literature that constitutes almost the entire evidence base for TB-500 is, for tesamorelin, a footnote.

Early development history. Before HIV lipodystrophy, the compound was under investigation for wasting, hip fracture recovery, immune disorders, sleep maintenance insomnia and mild cognitive impairment ³.

Most of those programmes did not produce approvals, which is the normal fate of most indications a compound is tried in, and worth stating plainly given how often the informal literature treats early-stage interest as evidence.

How the wider literature positions it. Reviews written for orthopaedic, sports medicine and endocrine audiences consistently place tesamorelin in a different category from the unapproved growth hormone secretagogues it is grouped with commercially, naming it as the approved member of a class whose other members are not ^20,21,22,25, while reviews of peptide use in sport note its appearance in self-administration protocols regardless ²³.

Every independent review that distinguishes approved from unapproved compounds in this space puts tesamorelin on one side of that line and everything else in Family B on the other.

05 · Evidence overview

06 · Safety profile

Class liability. Tesamorelin has major effects on glucose and lipid metabolism, which follows directly from raising growth hormone ¹¹. Impaired glucose tolerance is the predictable consequence of the mechanism, monitored in trials and tracked in post-marketing studies, where hyperglycaemia frequency was reported as similar between tesamorelin and comparator groups in people on integrase inhibitors ¹⁸.

Hepatic. The drug-induced liver injury profile is catalogued in the National Institute of Diabetes and Digestive and Kidney Diseases LiverTox resource ¹¹ — a level of systematic hepatic safety documentation that exists because the compound went through an approval pathway, and that has no counterpart for any unapproved compound in this roadmap.

Tolerability in trials. Reviews of the approval-supporting programme describe tesamorelin as generally well tolerated, with the treatment-related adverse event profile characterised in the regulatory submissions and summarised in the independent clinical review ^8,9,12.

What is genuinely unknown. Long-term use beyond the durations studied in the approval programme and its extensions. Effects in populations outside the approved indication — the neurocognition trial is the only substantial published test outside it, and it was null and underpowered ¹⁹. Whether the hepatic benefits observed in HIV-associated NAFLD extend to NAFLD without HIV, which has not been established. Interaction with the current generation of weight-lowering agents. And, most relevant to how this class is discussed generally, whether any of the findings in a population with HIV-associated lipodystrophy — a specific pathophysiology involving antiretroviral-associated fat redistribution — transfer to people without that condition. No study has addressed that question.

07 · US regulatory status

Current as of 6 September 2026. Tesamorelin was approved by the US Food and Drug Administration in November 2010, marketed as Egrifta by Theratechnologies with EMD Serono, for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy ⁶. It is not a controlled substance.

The indication is narrow and quantitatively defined. Canadian health technology assessment describes the treatment population as patients with excess visceral adipose tissue assessed by waist circumference of 95 cm or more in males and 94 cm or more in females and confirmed at more than 130 cm² by computed tomography, in treatment-experienced patients ¹⁰. Use outside that population is off-label.

Tesamorelin does not appear in FDA’s category 2 bulk drug substances tables and was not among the substances reviewed by FDA’s Pharmacy Compounding Advisory Committee in July 2026 — it does not need to be, because it is an approved drug product rather than a bulk substance nominated for compounding.

Under the World Anti-Doping Code, growth hormone-releasing factors and their analogues are prohibited at all times, and validated urine detection methods for tesamorelin have been published ^16,24. Competitors should consult the current Prohibited List directly rather than rely on secondary summaries, including this one.

08 · Limitations of the evidence

1. The approval covers one population, defined by disease and by imaging. HIV-associated lipodystrophy involves antiretroviral-associated fat redistribution with a specific pathophysiology ^9,10. Nothing in the approval package speaks to visceral fat in people without HIV, and no trial has tested that question.

1. The one substantial trial outside the indication was null. Tesamorelin reduced waist circumference but produced no significant cognitive benefit in people with HIV and abdominal obesity, in a study its authors described as insufficiently powered and lacking a placebo arm ¹⁹. Underpowered and null is weak evidence of absence — and it is the only test there is.

1. Metabolic liability is intrinsic to the mechanism. Raising growth hormone antagonises insulin action, and the compound has major effects on glucose and lipid metabolism ¹¹. This is not a manageable side effect to be designed away; it is the same axis the therapeutic effect runs on.

1. Hepatic findings are promising and preliminary. The NAFLD work is mechanistically serious ^13,14 and remains confined to a population with HIV, with gene-expression and fibrosis-score endpoints rather than clinical outcomes such as progression to cirrhosis.

1. Early literature is sponsor-linked. Drug evaluations and reviews from the development period ^3,7,8,12 were written while the compound was in commercial development. The independent weight in this file comes from the HTA review ^9,10 and the academic post-marketing work.

1. Duration is bounded. The pivotal endpoints were assessed at 26 weeks ^15,17. Lipodystrophy is a chronic condition, and evidence for use over years rests on extension data rather than on trials designed to answer that question.

1. An approval is not a general endorsement. This is the limitation most often ignored when tesamorelin is cited in support of the GHRH class. The approval establishes that a specific preparation, at a specific dose, in a specific population, achieved a specific measured endpoint with an acceptable risk profile. It establishes nothing about other GHRH analogues, other populations, or other endpoints.

09 · References

1. Grossman A, Savage MO, Besser GM. Growth hormone releasing hormone. Clin Endocrinol Metab. 1986;15(3):607–627.

   PMID 2429796 ↗

2. Esposito P, Barbero L, Caccia P, et al. PEGylation of growth hormone-releasing hormone (GRF) analogues. Adv Drug Deliv Rev. 2003;55(10):1279–1291.

   PMID 14499707 ↗

3. Tomlinson B. Drug evaluation: tesamorelin, a synthetic human growth hormone releasing factor. Curr Opin Investig Drugs. 2006;7(10):936–945.

   PMID 17086939 ↗

4. Wang Y, Tomlinson B. Tesamorelin, a human growth hormone releasing factor analogue. Expert Opin Investig Drugs. 2009;18(3):303–310.

   PMID 19243281 ↗

5. Dhillon S. Spotlight on tesamorelin in HIV-associated lipodystrophy. BioDrugs. 2011;25(6):405–408.

   PMID 22050344 ↗

6. Grunfeld C, Dritselis A, Kirkpatrick P. Tesamorelin. Nat Rev Drug Discov. 2011;10(2):95–96.

   PMID 21283099 ↗

7. Dhillon S. Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy. Drugs. 2011;71(8):1071–1091.

   PMID 21668043 ↗

8. Spooner LM, Olin JL. Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy. Ann Pharmacother. 2012;46(2):240–247.

   PMID 22298602 ↗

9. Canadian Agency for Drugs and Technologies in Health. Clinical Review Report: Tesamorelin (Egrifta). Ottawa; 2016.

   PMID 30920787 ↗

10. Canadian Agency for Drugs and Technologies in Health. Pharmacoeconomic Review Report: Tesamorelin (Egrifta). Ottawa; 2016.

    PMID 30896905 ↗

11. National Institute of Diabetes and Digestive and Kidney Diseases. Tesamorelin. In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda; 2018.

    PMID 31644039 ↗

12. Audsley J, Sasadeusz J, Lewin SR. Tesamorelin, liver fat, and NAFLD in the setting of HIV. Lancet HIV. 2019;6(12):e808–e809.

    PMID 31611037 ↗

13. Fourman LT, Billingsley JM, Agyapong G, et al. Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD. JCI Insight. 2020;5(16):e140134.

    PMID 32701508 ↗

14. Fourman LT, Stanley TL, Billingsley JM, et al. Delineating tesamorelin response pathways in HIV-associated NAFLD using a targeted proteomic and transcriptomic approach. Sci Rep. 2021;11(1):10485.

    PMID 34006921 ↗

15. Lake JE, La K, Erlandson KM, et al. Tesamorelin improves fat quality independent of changes in fat quantity. AIDS. 2021;35(9):1395–1402.

    PMID 33756511 ↗

16. Memdouh S, Gavrilović I, Ng K, Cowan D, Abbate V. Advances in the detection of growth hormone releasing hormone synthetic analogs. Drug Test Anal. 2021;13(11–12):1871–1887.

    PMID 34665524 ↗

17. Rahman F, McLaughlin T, Mesquita P, et al. Effect of tesamorelin in people with HIV with and without dorsocervical fat: post hoc analysis of phase III double-blind placebo-controlled trial. J Clin Transl Sci. 2022;7(1):e40.

    PMID 36845310 ↗

18. Russo SC, Ockene MW, Arpante AK, et al. Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors. AIDS. 2024;38(12):1758–1764.

    PMID 38905488 ↗

19. Ellis RJ, Vaida F, Hu K, et al. Effects of tesamorelin on neurocognitive impairment in persons with HIV and abdominal obesity. J Infect Dis. 2025;231(5):1230–1238.

    PMID 39813152 ↗

20. Rahman OF, Lee SJ, Seeds WA. Therapeutic peptides in orthopaedics: applications, challenges, and future directions. J Am Acad Orthop Surg Glob Res Rev. 2026;10(1):e25.00236.

    PMID 41490200 ↗

21. Mayfield CK, Bolia IK, Feingold CL, et al. Injectable peptide therapy: a primer for orthopaedic and sports medicine physicians. Am J Sports Med. 2026;54(1):223–229.

    PMID 41476424 ↗

22. Mendias CL, Awan TM. Safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance. Sports Med. 2026;56(8):1921–1935.

    PMID 41966639 ↗

23. Coutinho LFD, de Oliveira Neves LF, Camilo RP. A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review. J Sports Med Phys Fitness. 2026;66(7):880–885.

    PMID 41880199 ↗

24. Uçaktürk E, Nemutlu E. Analysis of growth hormone releasing hormone and its analogs in urine using nano liquid chromatography coupled with quadrupole/orbitrap mass spectrometry. J Pharm Biomed Anal. 2026;268:117207.

    PMID 41138283 ↗

25. Dominikowski A, Rękoś Z, Olejarz M, Szczepanek-Parulska E, Domin R, Ruchała M. The emerging landscape of performance-enhancing peptides modulating the GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Front Endocrinol (Lausanne). 2026;17:1822475.

    PMID 42395176 ↗